Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism
| Autor: | Pedro Dorado, Idilio González, Adrián LLerena, Fernando de Andrés, Luis R Calzadilla, Eva M Peñas-Lledó, María Eugenia G Naranjo |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Genotype Population Bioinformatics digestive system 030226 pharmacology & pharmacy Biochemistry 03 medical and health sciences 0302 clinical medicine Genotype-phenotype distinction Genetics Humans Medicine Precision Medicine skin and connective tissue diseases education Molecular Biology Genotyping education.field_of_study business.industry Cuba Precision medicine Healthy Volunteers Phenotype Cytochrome P-450 CYP2D6 Pharmacogenetics 030220 oncology & carcinogenesis Pharmacogenomics Molecular Medicine Female Personalized medicine business Biotechnology |
| Zdroj: | OMICS: A Journal of Integrative Biology. 21:17-26 |
| ISSN: | 1557-8100 |
| DOI: | 10.1089/omi.2016.0166 |
| Popis: | A long-standing question and dilemma in precision medicine is whether and to what extent genotyping or phenotyping drug metabolizing enzymes such as CYP2D6 can be used in real-life global clinical and societal settings. Although in an ideal world using both genotype and phenotype biomarkers are desirable, this is not always feasible for economic and practical reasons. Moreover, an additional barrier for clinical implementation of precision medicine is the lack of correlation between genotype and phenotype, considering that most of the current methods include only genotyping. Thus, the present study evaluated, using dextromethorphan as a phenotyping probe, the relationship between CYP2D6 phenotype and CYP2D6 genotype, especially for the ultrarapid metabolizer (UM) phenotype. We report in this study, to the best of our knowledge, the first comparative clinical pharmacogenomics study in a Cuban population sample (N = 174 healthy volunteers) and show that the CYP2D6 genotype is not a robust predictor of the CYP2D6 ultrarapid metabolizer (mUM) status in Cubans. Importantly, the ultrarapid CYP2D6 phenotype can result in a host of health outcomes, such as drug resistance associated with subtherapeutic drug concentrations, overexposure to active drug metabolites, and altered sensitivity to certain human diseases by virtue of altered metabolism of endogenous substrates of CYP2D6. Hence, phenotyping tests for CYP2D6 UMs appear to be a particular necessity for precision medicine in the Cuban population. Finally, in consideration of ethical and inclusive representation in global science, we recommend further precision medicine biomarker research and funding in support of neglected or understudied populations worldwide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|